295 related articles for article (PubMed ID: 8413437)
1. The organization of medical care. Lessons from the Medicare end stage renal disease program.
Levinsky NG
N Engl J Med; 1993 Nov; 329(19):1395-9. PubMed ID: 8413437
[No Abstract] [Full Text] [Related]
2. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access.
Lee H; Manns B; Taub K; Ghali WA; Dean S; Johnson D; Donaldson C
Am J Kidney Dis; 2002 Sep; 40(3):611-22. PubMed ID: 12200814
[TBL] [Abstract][Full Text] [Related]
3. Extension of Medicare immunosuppressive drug benefits: a "no brainer" that did not happen.
Bennett WM
Clin J Am Soc Nephrol; 2010 May; 5(5):743. PubMed ID: 20448072
[No Abstract] [Full Text] [Related]
4. Can we revitalize the ESRD program?
McFeeley T
Nephrol News Issues; 2004 Apr; 18(5):42-3, 47, 87. PubMed ID: 15125164
[No Abstract] [Full Text] [Related]
5. The politics of health cost containment: end-stage renal disease.
Rettig RA
Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928
[No Abstract] [Full Text] [Related]
6. The American health care system. The End Stage Renal Disease Program.
Iglehart JK
N Engl J Med; 1993 Feb; 328(5):366-71. PubMed ID: 8419833
[No Abstract] [Full Text] [Related]
7. The 2011 ESRD prospective payment system: an uncontrolled experiment.
Winkelmayer WC; Chertow GM
Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428
[No Abstract] [Full Text] [Related]
8. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
Lowrie EG; Hampers CL
N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
[TBL] [Abstract][Full Text] [Related]
9. Adapting to changes in Medicare cost report requirements.
Rossi T
Nephrol News Issues; 2005 Sep; 19(10):36-9. PubMed ID: 16187645
[No Abstract] [Full Text] [Related]
10. Medicare program; end-stage renal disease prospective payment system. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
[TBL] [Abstract][Full Text] [Related]
11. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization.
Lacson E; Hakim RM
Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423
[No Abstract] [Full Text] [Related]
12. The direction of end-stage renal disease reimbursement in the United States.
Lockridge RS
Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
[TBL] [Abstract][Full Text] [Related]
13. Is it time for Medicare to provide reimbursement for daily hemodialysis?
Newmann JM
Nephrol News Issues; 2001 Apr; 15(5):57-9. PubMed ID: 12108965
[No Abstract] [Full Text] [Related]
14. The public cost of kidney disease.
Ruchlin HS
Soc Work Health Care; 1984; 9(4):1-9. PubMed ID: 6385310
[TBL] [Abstract][Full Text] [Related]
15. The first DRG: lessons from the end stage renal disease program for the prospective payment system.
Maxwell JH; Sapolsky HM
Inquiry; 1987; 24(1):57-67. PubMed ID: 2951335
[TBL] [Abstract][Full Text] [Related]
16. KI study: older patients with CKD are costly as they transition to dialysis.
St Peter W
Nephrol News Issues; 2004 Oct; 18(11):85. PubMed ID: 15551617
[No Abstract] [Full Text] [Related]
17. The medical directorship of renal dialysis facilities under the new Medicare conditions for coverage: challenges and opportunities.
DeOreo PB
Blood Purif; 2009; 27(1):16-21. PubMed ID: 19169012
[TBL] [Abstract][Full Text] [Related]
18. What price success?
Tecnologica; 1996 Nov; ():1-6. PubMed ID: 10179816
[No Abstract] [Full Text] [Related]
19. Conditions for coverage fail to relieve administrative burden.
Wish D
Nephrol News Issues; 2005 Sep; 19(10):46-7, 51. PubMed ID: 16187648
[No Abstract] [Full Text] [Related]
20. Should the medicare ESRD program pay for daily dialysis? An ethical analysis.
Anantharaman P; Moss AH
Adv Chronic Kidney Dis; 2007 Jul; 14(3):290-6. PubMed ID: 17603984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
